1. Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.
- Author
-
Wille K, Dumke M, Wilsdorf N, Sadjadian P, Schneider A, Jender-Bartling S, Kolatzki V, Horstmann A, Meixner R, Jiménez-Muñoz M, Fuchs C, Tischler HJ, and Griesshammer M
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Retrospective Studies, Idarubicin administration & dosage, Vidarabine analogs & derivatives, Vidarabine administration & dosage, Vidarabine therapeutic use, Treatment Outcome, Recurrence, Salvage Therapy, Drug Resistance, Neoplasm, Prognosis, Aged, 80 and over, Granulocyte Colony-Stimulating Factor, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Sulfonamides administration & dosage, Sulfonamides therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute diagnosis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cytarabine administration & dosage, Cytarabine therapeutic use
- Abstract
Introduction: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes., Patients and Methods: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0 months compared standard salvage chemotherapy (FLAG-Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy., Results: Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log-rank-test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group., Conclusions: The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy., (© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2025
- Full Text
- View/download PDF